BMS Partners with Repare on Synthetic Lethal Target Discovery for US$65 M Upfront
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 6 (Table of Contents)
Published: 3 Jun-2020
DOI: 10.3833/pdr.v2020.i6.2540 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Bristol Myers Squibb (BMS) has entered into a worldwide research collaboration with Repare Therapeutics to utilise its CRISPR-enabled genome-wide synthetic lethal target discovery platform, SNIPRx®, to develop therapeutics that target specific vulnerabilities of tumours in genetically defined patient populations...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS